- Home
- EVTV vs GLTO Comparison
EVTV vs GLTO Comparison
Compare EVTV & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVTV
- GLTO
- Stock Information
- Founded
- EVTV 2012
- GLTO 2011
- Country
- EVTV United States
- GLTO Denmark
- Employees
- EVTV N/A
- GLTO N/A
- Industry
- EVTV Auto Manufacturing
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- EVTV Consumer Discretionary
- GLTO Health Care
- Exchange
- EVTV Nasdaq
- GLTO Nasdaq
- Market Cap
- EVTV 4.3M
- GLTO 4.5M
- IPO Year
- EVTV 2017
- GLTO 2020
- Fundamental
- Price
- EVTV $0.17
- GLTO $3.22
- Analyst Decision
- EVTV
- GLTO Buy
- Analyst Count
- EVTV 0
- GLTO 1
- Target Price
- EVTV N/A
- GLTO $10.00
- AVG Volume (30 Days)
- EVTV 724.2K
- GLTO 25.4K
- Earning Date
- EVTV 08-13-2025
- GLTO 08-11-2025
- Dividend Yield
- EVTV N/A
- GLTO N/A
- EPS Growth
- EVTV N/A
- GLTO N/A
- EPS
- EVTV N/A
- GLTO N/A
- Revenue
- EVTV $1,650,137.00
- GLTO N/A
- Revenue This Year
- EVTV N/A
- GLTO N/A
- Revenue Next Year
- EVTV N/A
- GLTO N/A
- P/E Ratio
- EVTV N/A
- GLTO N/A
- Revenue Growth
- EVTV N/A
- GLTO N/A
- 52 Week Low
- EVTV $0.15
- GLTO $2.01
- 52 Week High
- EVTV $2.61
- GLTO $15.13
- Technical
- Relative Strength Index (RSI)
- EVTV 39.20
- GLTO 39.53
- Support Level
- EVTV $0.18
- GLTO $3.12
- Resistance Level
- EVTV $0.20
- GLTO $3.94
- Average True Range (ATR)
- EVTV 0.02
- GLTO 0.30
- MACD
- EVTV -0.00
- GLTO -0.05
- Stochastic Oscillator
- EVTV 7.95
- GLTO 10.54
About EVTV Envirotech Vehicles Inc.
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.